BioCentury
ARTICLE | Clinical News

FDA approves Bayer's recombinant Factor VIII for hemophilia A

August 31, 2018 6:02 PM UTC

FDA approved a BLA from Bayer AG (Xetra:BAYN) for Jivi damoctocog alfa pegol (BAY94-9027) to treat hemophilia A in patients ages 12 and older. Bayer told BioCentury the product will be launched the first week of September and at a price competitive to other hemophilia drugs in its class.

Jivi is a pegylated recombinant form of human Factor VIII (rFVIII)...

BCIQ Company Profiles

Bayer AG

BCIQ Target Profiles

Factor VIIa